semaglutide patent expiration us Indian pharma companies launch low-cost generic Semaglutide patent expiry in India

Kokkorakis M, Katsarou A, Katsiki N, Mantzoros CS

Semaglutide (Wegovy and Ozempic) is FDA-approved for managing blood sugar levels in patients with type 2 diabetes mellitus and promoting weight loss in obese and overweight patients with at least one weight-related health condition, when used along with lifestyle changes such as a low-calorie diet and increased physical activity

We invite you to consult with our experienced healthcare professionals to explore these treatment options and how they can fit into your health and wellness goals

Samfundsbetydning Millioner af patienter verden over med type 2-diabetes og svr overvgt kan nu behandles effektivt med de nye GLP-1 lgemidler, og samtidig kan flgesygdomme og organskade begrnses

Slower Gastric Emptying: Food stays in your stomach longer, contributing to feeling full and satisfied